The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.
Fiche du document
7 mars 2019
- doi: 10.1016/j.stem.2019.02.012
- issn: 1875-9777
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.stem.2019.02.012
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30849366
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1875-9777
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_9C9755E6E69D1
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Mouse House mice Mus musculus House mouseCiter ce document
N. Vannini et al., « The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. », Serveur académique Lausannois, ID : 10.1016/j.stem.2019.02.012
Métriques
Partage / Export
Résumé
It has been recently shown that increased oxidative phosphorylation, as reflected by increased mitochondrial activity, together with impairment of the mitochondrial stress response, can severely compromise hematopoietic stem cell (HSC) regeneration. Here we show that the NAD + -boosting agent nicotinamide riboside (NR) reduces mitochondrial activity within HSCs through increased mitochondrial clearance, leading to increased asymmetric HSC divisions. NR dietary supplementation results in a significantly enlarged pool of progenitors, without concurrent HSC exhaustion, improves survival by 80%, and accelerates blood recovery after murine lethal irradiation and limiting-HSC transplantation. In immune-deficient mice, NR increased the production of human leucocytes from hCD34+ progenitors. Our work demonstrates for the first time a positive effect of NAD + -boosting strategies on the most primitive blood stem cells, establishing a link between HSC mitochondrial stress, mitophagy, and stem-cell fate decision, and unveiling the potential of NR to improve recovery of patients suffering from hematological failure including post chemo- and radiotherapy.